Trilogy Capital Inc. Mannkind Corp Transaction History
Trilogy Capital Inc.
- $1.89 Billion
- Q4 2024
Shares
2 transactions
Others Institutions Holding MNKD
# of Institutions
260Shares Held
161MCall Options Held
1.97MPut Options Held
943K-
Black Rock Inc. New York, NY22.6MShares$120 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA16.1MShares$85.4 Million0.0% of portfolio
-
State Street Corp Boston, MA9.95MShares$52.9 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.75MShares$46.6 Million0.82% of portfolio
-
Nitorum Capital, L.P. New York, NY8.75MShares$46.5 Million8.23% of portfolio
About MANNKIND CORP
- Ticker MNKD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 257,338,000
- Market Cap $1.37B
- Description
- MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...